arixtra study in new england journal Overnight gsk announced that the Arixtra ACS study was reported in the New England Journal of Medicine. The more Arixtra gets known about, the better.
Here's a snippet of their ann, for those interested:
...............
Arixtra® significantly reduced major bleeding compared to Lovenox® in a study of patients with acute coronary syndromes
Head-to-Head Data Published in New England Journal of Medicine Report:
PHILADELPHIA, PA, April 6, 2006 — Data published today in the New England Journal of Medicine from OASIS 5, one of the largest clinical trials ever conducted in patients with acute coronary syndromes (ACS),demonstrated that treatment with the antithrombotic medicine, ARIXTRA® (fondaparinux sodium) significantly reduced major bleeding by nearly half (48 percent) as compared to Lovenox® at day 9. The resultsshowed ARIXTRA, manufactured by GlaxoSmithKline, demonstrated comparable efficacy to Lovenox® at day 9.
- Forums
- ASX - By Stock
- time to switch to mtr?
arixtra study in new england journal Overnight gsk announced...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable